- Home
- ONCO vs ADXN Comparison
ONCO vs ADXN Comparison
Compare ONCO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | ADXN |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 10.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONCO | ADXN |
|---|---|---|
| Price | $1.39 | $7.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 53.7K | 7.1K |
| Earning Date | 11-13-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,223,751.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.42 | $6.51 |
| 52 Week High | $179.35 | $12.05 |
Technical Indicators
Market Signals| Indicator | ONCO | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 26.63 | 45.59 |
| Support Level | $1.54 | $7.48 |
| Resistance Level | $1.66 | $8.90 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 3.07 | 35.45 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.